Dr. Taylor on Treatments in Development for Endometrial Cancer

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

There is a better knowledge of the molecular changes that can guide physicians toward specific pathways where targeted agents may have activity, explain Taylor.

According to Taylor, there are many phase II studies investigating single-agent targeted therapies, particularly with the mTOR inhibitors targeting the PI3-kinase pathway, as well as the antiangiogenic agents.

Related Videos
View All
Related Content